SELLAS Life Sciences (SLS) Cash from Financing Activities (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Cash from Financing Activities data on file, last reported at $44.2 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 87.23% year-over-year to $44.2 million in Q1 2026; TTM through Mar 2026 was $106.9 million, a 144.58% increase from a year earlier, with the FY2025 full-year figure at $86.3 million, up 84.56% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $44.2 million, up from $32.4 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for SLS reached as high as $44.2 million in Q1 2026 and fell as low as -$29000.0 in Q2 2023.
• Historically, Cash from Financing Activities has averaged $13.2 million across 5 years, with a median of $4.2 million in 2025.
• Across the five-year window, Cash from Financing Activities sank 100.13% in 2023 and jumped 404825.0% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $929000.0 in 2022, then surged by 264.48% to $3.4 million in 2023, then plunged by 99.76% to $8000.0 in 2024, then soared by 404825.0% to $32.4 million in 2025, then jumped by 36.29% to $44.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $44.2 million in Q1 2026, $32.4 million in Q4 2025, and $26.1 million in Q3 2025.